Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–positive breast cancer

  1. Pivot, X.
  2. Pegram, M.
  3. Cortes, J.
  4. Lüftner, D.
  5. Lyman, G.H.
  6. Curigliano, G.
  7. Bondarenko, I.
  8. Yoon, Y.C.
  9. Kim, Y.
  10. Kim, C.
Revista:
European Journal of Cancer

ISSN: 1879-0852,  0959-8049

Any de publicació: 2019

Volum: 120

Pàgines: 1-9

Tipus: Article

DOI: 10.1016/J.EJCA.2019.07.015 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus